Type-1 interferons contribute to the neuroinflammatory response and disease progression of the MPTP mouse model of Parkinson's disease

GLIA

Volumn 64, Issue 9, 2016, Pages 1590-1604

  Main, Bevan S ^a   Zhang, Moses ^a   Brody, Kate M ^a   Ayton, Scott ^b   Frugier, Tony ^a   Steer, David ^c   Finkelstein, David ^b   Crack, Peter J ^a   Taylor, Juliet M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

interferons; microglia; MPTP; neuroinflammation; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; IMMUNOGLOBULIN G ANTIBODY; INTERFERON; INTERFERON RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MAR 1; UNCLASSIFIED DRUG;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CELL DEATH; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; MALE; MOUSE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84978966712     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.23028     Document Type: Article

References (57)

1. Almeida CM, Galvao Mde L, Ferreira PL, Braga WS. 2009. Interferon-induced Parkinsonism in a patient with chronic hepatitis C. Arq Neuropsiquiatr 67:715–716.
2. Arai H, Furuya T, Yasuda T, Miura M, Mizuno Y, Mochizuki H. 2004. Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and expression of caspase-11 in mice. J Biol Chem 279:51647–51653.
3. Baruch K, Deczkowska A, David E, Castellano JM, Miller O, Kertser A, Berkutzki T, Barnett-Itzhaki Z, Bezalel D, Wyss-Coray T, Amit I, Schwartz M. 2014. Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 346:89–93.
4. Bergquist F, Shahabi HN, Nissbrandt H. 2003. Somatodendritic dopamine release in rat substantia nigra influences motor performance on the accelerating rod. Brain Res 973:81–91.
5. Bersano A, Aghemo A, Rumi MG, Ballabio E, Candelise L, Colombo M. 2008. Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism. Eur J Intern Med 19:370–371.
6. Beurel E, Jope RS. 2009. Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain. J Neuroinflammation 6:9-
7. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S. 2009. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119:182–192.
8. Cherry JD, Olschowka JA, O'Banion MK. 2014. Neuroinflammation and M2 microglia: The good, the bad, and the inflamed. J Neuroinflammation 11:98
9. Chung YC, Kim Y-S, Bok E, Yune TY, Maeng S, Jin BK. 2013. MMP-3 contributes to nigrostriatal dopaminergic neuronal loss, BBB damage, and neuroinflammation in an MPTP mouse model of Parkinson's disease. Mediat Inflamm 2013:11
10. Cox DJ, Field RH, Williams DG, Baran M, Bowie AG, Cunningham C, Dunne A. 2015. DNA sensors are expressed in astrocytes and microglia in vitro and are upregulated during gliosis in neurodegenerative disease. Glia 63:812–825.
11. Czlonkowska A, Kohutnicka M, Kurkowska-Jastrzebska I, Czlonkowski A. 1996. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 5:137–143.
12. de Lau LM, Breteler MM. 2006. Epidemiology of Parkinson's disease. Lancet Neurol 5:525–535.
13. de Weerd NA, Nguyen T. 2012. The interferons and their receptors—Distribution and regulation. Immunol Cell Biol 90:483–491.
14. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, Paul SM. 2001. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 98:14669–14674.
15. Ejlerskov P, Hultberg JG, Wang J, Carlsson R, Ambjorn M, Kuss M, Liu Y, Porcu G, Kolkova K Friis Rundsten C, et al. 2015. Lack of neuronal IFN-beta-IFNAR causes lewy body- and Parkinson's disease-like dementia. Cell 163:324–339.
16. Ferger B, Leng A, Mura A, Hengerer B, Feldon J. 2004. Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J Neurochem 89:822–833.
17. Gao HM, Zhang F, Zhou H, Kam W, Wilson B, Hong JS. 2011. Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ Health Perspect 119:807–814.
18. Gillardon F, Schmid R, Draheim H. 2012. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 208:41–58.
19. Hamner MA, Ye Z, Lee RV, Colman JR, Le T, Gong DC, Ransom BR, Weinstein JR. 2015. Ischemic Preconditioning in White Matter: Magnitude and Mechanism. J Neurosci 35:15599–15611.
20. Ho HH, Ivashkiv LB. 2006. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem 281:14111–14118.
21. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, Taniguchi T. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434:772–777.
22. Hows ME, Ashmeade TE, Billinton A, Perren MJ, Austin AA, Virley DJ, Organ AJ, Shah AJ. 2004. High-performance liquid chromatography/tandem mass spectrometry assay for the determination of 1-methyl-4-phenyl pyridinium (MPP+) in brain tissue homogenates. J Neurosci Methods 137:221–226.
23. Hung LW, Villemagne VL, Cheng L, Sherratt NA, Ayton S, White AR, Crouch PJ, Lim S, Leong SL, Wilkins S, George J, Roberts BR, Pham CL, Liu X, Chiu FC, Shackleford DM, Powell AK, Masters CL, Bush AI, O'Keefe G, Culvenor JG, Cappai R, Cherny RA, Donnelly PS, Hill AF, Finkelstein DI, Barnham KJ. 2012. The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease. J Exp Med 209:837–854.
24. Hunter RL, Cheng B, Choi DY, Liu M, Liu S, Cass WA, Bing G. 2009. Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J Neurosci Res 87:1913−1921.
25. Hwang SY, Hertzog PJ, Holland KA, Sumarsono SH, Tymms MJ, Hamilton JA, Whitty G, Bertoncello I, Kola I. 1995. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc Natl Acad Sci U S A 92:11284–11288.
26. Ikushima H, Negishi H, Taniguchi T. 2013. The IRF family transcription factors at the interface of innate and adaptive immune responses. Cold Spring Harb Symp Quant Biol 78:105–116.
27. Kajihara M, Montagnese S, Khanna P, Amodio P, Schapira AH, Dusheiko GM, Morgan MY. 2010. Parkinsonism in patients with chronic hepatitis C treated with interferon-alpha2b: A report of two cases. Eur J Gastroenterol Hepatol 22:628–631.
28. Karve IP, Zhang M, Habgood M, Frugier T, Brody KM, Sashindranath M, Joakim Ek CJ, Chappaz S, Kile BT, Wright D, Wang H, Johnston L, Daglas M, Ates RC, Medcalf RL, Taylor JM, Crack PJ. 2016. Ablation of type-1 IFN Signaling in hematopoietic cells confers protection following traumatic brain injury. eNeuro 18;3.
29. Kim B, Yang MS, Choi D, Kim JH, Kim HS, Seol W, Choi S, Jou I, Kim EY, Joe EH. 2012. Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One 7:e34693
30. Kortekaas R, Leenders KL, van Oostrom JCH, Vaalburg W, Bart J, Willemsen ATM, Hendrikse NH. 2005. Blood–brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57:176–179.
31. Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK, Wong BX, Adlard PA, Cherny RA, Lam LQ, Roberts BR, Volitakis I, Egan GF, McLean CA, Cappai R, Duce JA, Bush AI. 2012. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 18:291–295.
32. Martin HL, Santoro M, Mustafa S, Riedel G, Forrester JV, Teismann P. 2016. Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson's disease. Glia 64:386–395.
33. Masuda T, Tsuda M, Yoshinaga R, Tozaki-Saitoh H, Ozato K, Tamura T, Inoue K. 2012. IRF8 is a critical transcription factor for transforming microglia into a reactive phenotype. Cell Rep 1:334–340.
34. McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, Tansey KE, Tansey MG. 2006. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci 26:9365–9375.
35. McGeer PL, Itagaki S, Boyes BE, McGeer EG. 1988. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38:1285–1291.
36. Meredith GE, Totterdell S, Potashkin JA, Surmeier DJ. 2008. Modeling PD pathogenesis in mice: Advantages of a chronic MPTP protocol. Parkinsonism Relat Disord 14:S112–S115.
37. Mesquita SD, Ferreira AC, Gao F, Coppola G, Geschwind DH, Sousa JC, Correia-Neves M, Sousa N, Palha JA, Marques F. 2016. The choroid plexus transcriptome reveals changes in type I and II interferon responses in a mouse model of Alzheimer's disease. Brain Behav Immun 49;280–292.
38. Minten C, Terry R, Deffrasnes C, King NJ, Campbell IL. 2012. IFN regulatory factor 8 is a key constitutive determinant of the morphological and molecular properties of microglia in the CNS. PLoS One 7:e49851
39. Mizoi Y, Kaneko H, Oharazawa A, Kuroiwa H. 1997. [Parkinsonism in a patient receiving interferon alpha therapy for chronic hepatitis C]. Rinsho Shinkeigaku 37:54–6.
40. Moehle MS, Webber PJ, Tse T, Sukar N, Standaert DG, DeSilva TM, Cowell RM, West AB. 2012. LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 32:1602–1611.
41. Moehle MS, West AB. 2015. M1 and M2 immune activation in Parkinson's Disease: Foe and ally? Neuroscience 302:59–73.
42. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T. 1994. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180:147–150.
43. Mount MP, Lira A, Grimes D, Smith PD, Faucher S, Slack R, Anisman H, Hayley S, Park DS. 2007. Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci 27:3328–3337.
44. Ning S, Pagano JS, Barber GN. 2011. IRF7: Activation, regulation, modification and function. Genes Immun 12:399–414.
45. Noelker C, Morel L, Lescot T, Osterloh A, Alvarez-Fischer D, Breloer M, Henze C, Depboylu C, Skrzydelski D, Michel PP, Dodel RC, Lu L, Hirsch EC, Hunot S, Hartmann A. 2013. Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci Rep 3:1393
46. Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y. 1985. A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol 50:435–41.
47. Owens T, Owens R, Khorooshi A Wlodarczyk N., Asgari 2014. Interferons in the central nervous system: A few instruments play many tunes. Glia 62;339–355.
48. Roodveldt C, Christodoulou J, Dobson CM. 2008. Immunological features of alpha-synuclein in Parkinson's disease. J Cell Mol Med 12:1820–1829.
49. Samii A, Etminan M, Wiens MO, Jafari S. 2009. NSAID use and the risk of Parkinson's disease: Systematic review and meta-analysis of observational studies. Drugs Aging 26:769–779.
50. Sheehan KC, Lai KS, Dunn GP, Bruce AT, Diamond MS, Heutel JD, Dungo-Arthur C, Carrero JA, White JM, Hertzog PJ, Schreiber RD. 2006. Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J Interferon Cytokine Res 26:804–819.
51. Smeyne RJ, Jackson-Lewis V. 2005. The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 134:57–66.
52. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP. 2002. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's disease. FASEB J 16:1474–1476.
53. Tanaka T, Murakami K, Bando Y, Yoshida S. 2015. Interferon regulatory factor 7 participates in the M1-like microglial polarization switch. Glia 63:595–610.
54. Taylor JM, Minter MR, Newman AG, Zhang M, Adlard PA, Crack PJ. 2014. Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer's disease. Neurobiol Aging 35:1012–1023.
55. Winer J, Jung CK, Shackel I, Williams PM. 1999. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270:41–49.
56. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S. 2002. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22:1763–1771.
57. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J. 2005. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19:533–542.